skip to main content
Global Search Configuration
Sponsored by:

Citeline Pharma Intelligence Awards Japan Entry Deadline Monday, 10 July, 2023

Citeline Pharma Intelligence Awards Japan, now in its second year, will return to Tokyo on October 17, 2023, bringing together hundreds of leading innovators, to meet and network, discover new opportunities, and reflect on life-changing accomplishments made over the previous year.

The awards recognize outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market.

  • Entries close Monday, 10 July, 2023
  • There is no fee for entering
  • Tuesday, 17 October, 2023
  • Table prices start from $2380
  • The Palace Hotel, Tokyo, Japan

Categories cover the entire pharma and biotech lifecycle and include: Pharma Company of the Year, Best New Drug Award, Biotech Company of the Year, Best CRO/CDMO and Licensing Deal of the Year.

The Citeline Pharma Intelligence Awards Japan Categories 2023

Download the entry guide

Best New Drug

Sponsored by

The Best New Drug Award recognizes excellence in pharmaceutical development. In this category, the judges will be looking for the small-molecule, biological, cell/gene therapy, digital therapeutic or vaccine product approved in Japan during the qualifying period that represents the best therapeutic advance in its area.


To enter this category, please answer the following:

  • Brand and generic name, indication, company(ies) involved in its development (if more than one company, please detail the relationship between the parties).
  • Date and market of approval and launch
  • Mechanism of action. How is this differentiated from other products and how does it represent a step forward?
  • Outline evidence for clinical activity, for example summary results from registrational clinical trials. How does this translate into a meaningful therapeutic benefit for patients and over other drugs?
  • What is the potential market size of the candidate?

Who can Enter

Any recently launched new product is eligible to enter as long as it was approved in its first indication in Japan between 1 January 2022-30 June 2023. (Generic and biosimilar products are not eligible.)

Entrants must have played a key role in the development of the nominated product, for example as a sole licensee or co-developer responsible for clinical trials and/or regulatory submissions, and all company members of joint development or joint venture agreements should be disclosed in the application.

Executive of The Year

Designed to acknowledge excellence in leadership, the winner of this award will be the executive who has exhibited exemplary leadership throughout the qualifying period (1 January 2022-30 June 2023). Also important to the judges will be the executive’s career achievements, influence within the industry and characteristics that make a good leader, such as decisive and clear strategy, team building and employee welfare.


To enter this category, please answer the following:

  • Name, company and position of the entrant, and the date of taking up this post.
  • Entrant’s greatest achievements during the qualifying year? What has been the direct consequence on company performance?
  • How have these achievements strengthened the candidate’s influence within the industry?
  • Entrant’s greatest strengths as a leader? How did these have a bearing on their achievements this year?
  • What specific previous accomplishments helped with this success? For example, previous scientific or management experience.

Who can Enter

Entrants must hold a C-suite executive position and be employed by the company at the time of nomination.

Biotech Company of the Year 

Sponsored by

This award honors outstanding achievements by biotech companies over the qualifying period (1 January 2022-30 June 2023).


To enter this category, please answer the following:

  • The company’s most significant achievement during the year.
  • Accomplishments in terms of: bringing new products closer to market; raising funds; significant licensing or partnership deals; evidence that management has been able to make difficult decisions to progress the company and its products; using proprietary science or technologies for unmet medical needs; transition from early stage to more mature company.

Who can Enter

This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

Best Contract Research Organization/Contract Development Manufacturing Organization

This Award is to recognize contract research organizations or contract development and manufacturing organizations that provide full or specialist services to their clients and which have an office or other base (but not necessarily a head office) either in Japan or the Asia region, including Australia. Entrant companies must offer services in Japan, but the achievements listed in the entry form do not necessarily have to be trials or services/manufacturing conducted in Japan (for example, clinical trials conducted in China or Australia are also eligible).

Judging will consider the quality and benefits of services and relationships built with clients. For CROs, it will pay particular attention to innovative patient trial recruitment strategies brought to the table, while for CDMOs, novel, more efficient and/or lower cost production processes will be considered.


To enter this category, please answer the following:

  • What particular capabilities and strengths does the CRO/CDMO offer?
  • How has the company delivered results that exceed sponsor/partner expectations?
  • What innovations in patient recruitment strategy has the CRO/CDMO brought to its partner?
  • How has it improved its performance, for example, in its quality of data, timelines and transparency?
  • What steps is the CRO taking towards improving the collection and reporting of trial data, through new procedures and systems such as electronic data capture, storage and platforms?

Who can Enter

To qualify, candidates must draw on their achievements in the qualifying period (1 January 2022-30 June 2023).

Licensing Deal of The Year

Deals considered here are those that involve the licensing of a particular drug, project or group of R&D assets from one company to another for further development and/ or marketing. (This category does not include more complex, broad partnerships between companies, for example to explore particular therapeutic strategies or mechanisms of action.)

The judges will look at all aspects from monetary and strategic value to the benefits they give to both sides.


To enter this category, please answer the following:

  • Outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
  • Monetary value of the deal in up-front and milestone payments.
  • Countries and indications included in the deal and does it allow any party to enter new markets?
  • Strategic value of the licensed product to the licensee/licensor’s business.
  • Please explain how the licensed product was the best possible candidate to complement the rest of the licensee’s pipeline or particular disease franchise, or how it fit into the licensor’s business strategy.

Who can Enter

To qualify, licensing deals must have been closed during the qualifying period of (1 January 2022-30 June 2023).

Financing Deal of the Year *NEW*

This new Award seeks to reward successful and creative fundraising by pharma and biotech companies in Japan, which are either privately or publicly owned.


The basic criterion for this award is the total amount of money raised at one time – for example in a Series A (or later) funding round or through an IPO – but other factors should be considered as well. For example:

  • Did the financing attract a broad range of investor groups?
  • Did investors include groups that do not normally invest in pharma/biotech?
  • Were any particularly novel financial instruments or structures used?
  • Was the financing/IPO successful despite being launched in a challenging overall environment?

Who can Enter

The investment can take various forms, including grants and public-private partnership deals, to fundraising from venture capital and private equity partners and initial public offerings. The majority of the new funds should be earmarked for use in drug discovery and/or company development. The qualifying period is 1 January 2022-30 June 2023.

Pharma Company of The Year (chosen by Citeline)

The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying period of 1 January 2022-30 June 2023. This special award is chosen not by the independent judging panel but by our own senior editorial team, based on a variety of key metrics as below:


  • Financial performance compared with the same period in previous fiscal year.
  • How the company was able to advance its stated strategy, looking at most significant achievements over the year.
  • Progress in emerging markets.
  • New product launches including line-extensions and formulations.
  • Advances in the drug pipeline, including major clinical trial reports.

Who can Enter

You can nominate your own company but there is no shortlist and the winner is decided by our senior editorial team.

Lifetime Achievement Award (chosen by Citeline)

Sponsored by

The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their distinguished career in the biotech or pharmaceutical arena, primarily within industry.


All entry forms must include:

  • The name of the nominee.
  • The job title of the nominee (if applicable).
  • The company name (if applicable).
  • Your contact details.
  • The contact details of the nominee.

Who can Enter

We welcome nominees for consideration for this Award but the decision lies not with the independent judging panel but with our senior editorial team. The winner may be retired or semi-retired but will still be active in the industry in some capacity.

Any entry form should outline, in no more than 1,500 words, what the nominee has accomplished during his or her career and say why they are worthy of this Award.

The Judges

How to enter?

Read the criteria for each category from the drop-down categories above. Then click ‘Begin Entry’ against the category/ies you wish to enter. Complete the downloadable entry form and once completed, email this to the awards team before the entry deadline of Monday, July 10, 2023.

Want to sponsor an award?

Sponsorship provides a wealth of opportunities, from thought leadership to brand awareness and lead generation. Find out more about the numerous sponsorship opportunities available.

Sponsor Opportunities


Looking to attend the Citeline Pharma Intelligence Awards Japan? Book your table today for the awards!


Headline Sponsor

ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.

our 2023 sponsors

CMIC stands for Current Medical Information Center. In 1992, Dr. Kazuo Nakamura founded CMIC as the first Contract Research Organization (CRO) in Japan. CMIC Group is currently the largest clinical CRO in Japan, providing comprehensive services in drug development, clinical trial and clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge your drug development and manufacturing needs between the US and Japan. CMIC Group has over 7,000 employees and 25 sites globally.

EPS Holdings, Inc. is a healthcare solutions provider that has been handling all processes from drug discovery and development to sales, marketing, consulting, and various other solutions since its founding as a pioneer CRO in Japan in 1991.

In recent years, EPS Holdings, Inc. has been providing comprehensive solutions to pharmaceutical and medical device companies, medical institutions, and academia through our efforts in Big Data & AI, regenerative medicine, and other areas including SMO (Site Management Organization) and CSO (Contract Sales Organization). In 2021, EPS Holdings, Inc. launched an innovative medicine business and started services to support the clinical development of seeds originating at academic institutions and domestic and global biotech ventures and to support marketing in and outside Japan.

Today, the EPS Group has over 35 group companies and continues to evolve day by day with more than 7,800 employees. For more information, please visit our website.

About Syneos Health – Long Form (122 words)

Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.

Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit Syneos Health | Biopharma Solutions Organization & CRO or subscribe to our podcast.
Syneos Health | Biopharma Solutions Organization & CRO
The Syneos Health Podcast


The Citeline Pharma Intelligence Awards Japan are now in their second year of recognizing outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market. Take a look back at our previous Awards and winners.

Citeline Pharma Intelligence Awards 2022

The Citeline Pharma Intelligence Awards Faq's

Can my company enter more than one category?

Yes, if you meet the entry criteria, you are welcome to enter more than one category. Please submit an entry form for each category you wish to enter.

Can a PR or marketing agency complete and submit the entry form on my behalf?

Yes, there is a section on the entry form for them to do so.

My company is sponsoring the awards, are we still able to enter?

Yes, you can. However, you cannot enter a category in which you are sponsoring. For more details on sponsorship, please see the Sponsorship Guide.

I have a question or query about the information on the entry form. Who can I contact?

Please feel free to contact the Japanese Award Management Team ( If necessary, we will contact the judging committee for a response.

How can I confirm that my entry has been accepted?

After submitting your entry form, the Award Management Team will send you an email confirming receipt.

got a question about the awards?

Please enter your name
Please enter your email
Please enter your valid email
Please enter your question
Please accept the terms & conditions
Senior Events Manager